Pharmaceuticals & Biopharmaceuticals

Carlsbad, Calif. – September 13, 2026 -- Tyra Biosciences, Inc. (Nasdaq: TYRA) will hold a virtual fireside chat and one-on-one investor meetings at the Cantor Global Healthcare Conference 2026 on Wednesday, September 13, 2026 at 1:00 PM ET.

Clinical-stage biotech to address investors from New York event

The presentation, though based in New York, NY, will be conducted virtually, with a live webcast accessible via the "For Investors" section of Tyra's website. A replay will be made available following the session.

New York – September 13, 2026 -- Rosen Law Firm has filed a securities class action against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) covering purchasers of the company's securities between September 13, 2026 and September 13, 2026.

Lawsuit alleges Unicycive never audited its manufacturing vendor's facility

The complaint claims Unicycive had not inspected its third-party manufacturing vendor's plant or verified compliance with current good manufacturing practices, leaving the company without a reasonable basis to assert the vendor had fixed deficiencies previously cited by the U.S. Food and Drug Administration.

Cleveland – September 13, 2026 -- The Austin Company and its affiliate Austin Consulting will exhibit at the 2026 ISPE Annual Meeting and Expo, running October 18-21 at the Gaylord National Resort and Convention Center in National Harbor, Maryland.

Austin joins three Kajima-family builders at a shared booth

The Austin Company will share Booth 939 with fellow Kajima family members Cockram Construction, Batson-Cook Construction, and Rodgers Builders. The joint presence is designed to showcase combined design-build capabilities for complex facilities across pharmaceutical, biotechnology, life sciences, manufacturing, and industrial sectors.

Austin Consulting takes a dedicated booth for site strategy services

Adjacent to the Kajima booth, Austin Consulting will occupy Booth 940, focusing on site selection, location strategy, incentives advisory, due diligence, and investment planning for manufacturing and life sciences companies.

Shanghai – September 12, 2026 -- CorrectSequence Therapeutics (Correctseq) reported that its transformer Base Editor (tBE) therapy CS-101/CS-206 delivered durable clinical remission in patients with sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) across four distinct genetic backgrounds, according to a peer-reviewed study published in Cell Stem Cell on September 7, 2026.

The study, conducted with multiple research institutions, expands on earlier data showing five Chinese TDT patients treated with CS-101 all achieved transfusion independence. The new cohort includes four patients from Nigeria, Laos, Malaysia and Pakistan -- one with SCD and three with TDT -- covering genotypes βS/βS, β0/βE, and two β0/β0 variants with different mutation types.

Sugar Land, Texas – September 12, 2026 -- QuVa Pharma, Inc. has acquired a range of essential medications from Central Admixture Pharmacy Services, Inc. (CAPS) after CAPS decided to exit the 503B sterile compounding business.

QuVa to phase in acquired products starting later in 2026

QuVa expects to begin introducing selected products from the acquired portfolio in phases later in 2026, with plans to expand its offerings over the following six months. The deal covers critical medication categories including Cardioplegia, Neonatal Starter Bags and Heparin, products used directly in patient care at hospitals nationwide.

Salt Lake City – September 12, 2026 -- A decade-long study by ARUP Laboratories found that 50% of pregnancies with atypical prenatal cell-free DNA (cfDNA) screening results carried at least one clinically significant abnormality confirmed by follow-up testing, reshaping how providers should respond to inconclusive genetic screens.

ARUP analyzed over 200 atypical cfDNA cases spanning more than 10 years

Researchers reviewed more than 10 years of data and over 200 cases where atypical cfDNA screening results were followed by additional prenatal, postnatal, or maternal testing. The findings, published in Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics (ACMG), represent what ARUP describes as the largest study of its kind on atypical cfDNA findings.

New York – September 12, 2026 -- Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) and certain of its officers, alleging violations of federal securities laws tied to the company's handling of a third-party manufacturing vendor's compliance issues.

Lawsuit covers investors who purchased Unicycive stock between September 12, 2026 and September 12, 2026

The complaint alleges Unicycive failed to inspect or audit its third-party manufacturing vendor's facility for compliance with current good manufacturing practices (cGMP). As a result, the company allegedly lacked a reasonable basis to claim the vendor had remedied deficiencies previously cited by the U.S. Food and Drug Administration.

Shanghai – September 12, 2026 -- CorrectSequence Therapeutics (Correctseq) reported that its transformer Base Editor (tBE) therapy CS-101/CS-206 achieved full transfusion independence or elimination of vaso-occlusive crises (VOC) in four new patients from Nigeria, Laos, Malaysia and Pakistan, expanding on earlier results in five Chinese patients who all reached transfusion independence. The findings, published September 12, 2026 in Cell Stem Cell, cover patients with sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) carrying distinct genotypes, including βS/βS, β0/βE, and two β0/β0 variants.

Palo Alto, Calif. – September 12, 2026 -- Prezent Vivo, an AI-powered communication platform for the life sciences sector, has appointed Alice Choi as Chief Operating Officer, adding more than 30 years of medical communications experience to its leadership team.

Choi brings three decades of biopharma communications leadership to the role

Choi built her career at organizations including McCann Health and the Omnicom network, holding roles across client services, operations and commercial leadership. She began in academia, earning a master's degree and PhD before moving into medical communications, and has led teams delivering programs for biopharma clients throughout her career.

Sheridan – September 12, 2026 -- The global pharmaceutical contract development and manufacturing organization (CDMO) market is forecast to expand from $191 billion in 2026 to $270.3 billion by 2031, a compound annual growth rate of 7.2%, according to a new study by Wissen Research.

Outsourcing and biologics demand drive the growth trajectory

Pharmaceutical and biotechnology firms are increasingly outsourcing drug development and manufacturing to cut capital costs and refocus internal resources on R&D and commercialization. Demand for biologics, biosimilars, cell and gene therapies, antibody-drug conjugates, and mRNA-based medicines is pushing CDMOs to build specialized manufacturing platforms rather than remain peripheral service providers.